Extracellular Vesicles‐Derived Hybrid Nanoplatforms for Amplified CD47 Blockade‐Based Cancer Immunotherapy
Advanced Materials · 2023
DOI: 10.1002/adma.202303835 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2023. Verfasst von Lu Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, P. R. C…. Hauptthemen laut MEDLINE: Neoplasms, Extracellular Vesicles. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Nature Science Foundation of China, Six Talent Peaks Project in Jiangsu Province, 333 High-Level Talent Development Project in Jiangsu Province.
Abstract (Originalsprache)
Immunomodulation of tumor‐associated macrophages (TAMs) into tumor‐inhibiting M1‐like phenotype is a promising but challenging strategy. Cleverly, tumor cells overexpress CD47, a “don't eat me” signal that ligates with the signal regulatory protein alpha (SIRPα) on macrophages to escape phagocytosis. Thus, effective re‐education of TAMs into the “eat me” type and blocking the CD47‐SIRPα signaling play pivotal roles in tumor immunotherapy. Herein, it is reported that hybrid nanovesicles (hEL‐RS17) derived from extracellular vesicles of M1 macrophages and decorated with RS17 peptide, an antitumor peptide that specifically binds to CD47 on tumor cells and blocks CD47‐SIRP α signaling, can actively target tumor cells and remodel TAM phenotypes. Consequently, more M1‐like TAMs infiltrate into tumor tissue to phagocytize more tumor cells due to CD47 blockade. By further co‐encapsulating chemotherapeutic agent shikonin, photosensitizer IR820, and immunomodulator polymetformin in hEL‐RS17, an enhanced antitumor effect is obtained due to the combinational treatment modality and close synergy among each component. Upon laser irradiation, the designed SPI@hEL‐RS17 nanoparticles exert potent antitumor efficacy against both 4T1 breast tumor and B16F10 melanoma models, which not only suppresses primary tumor growth but also inhibits lung metastasis and prevents tumor recurrence, exhibiting great potential in boosting CD47 blockade‐based antitumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, P. R. China.
- NMPA Key Laboratory for Research and Evaluation of Cosmetics, China Pharmaceutical University, Nanjing, 210009, P. R. China.
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, No. 11, First North Road, Zhongguancun, Beiji…
- University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
ORCID-Profile: Xing-Jie Liang
Förderung
- National Nature Science Foundation of China
- Six Talent Peaks Project in Jiangsu Province
- 333 High-Level Talent Development Project in Jiangsu Province
- Double First-Rate Construction Plan of China Pharmaceutical University
- National Natural Science Foundation of China
Zitieren
APA
Tang, L., Yin, Y., Cao, Y., Fu, C., Liu, H., Feng, J., Wang, W., & Liang, X. J. (2023). Extracellular Vesicles‐Derived Hybrid Nanoplatforms for Amplified CD47 Blockade‐Based Cancer Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202303835
Vancouver
Tang L, Yin Y, Cao Y, Fu C, Liu H, Feng J, et al. Extracellular Vesicles‐Derived Hybrid Nanoplatforms for Amplified CD47 Blockade‐Based Cancer Immunotherapy. Advanced Materials. 2023. doi:10.1002/adma.202303835
BibTeX
@article{Tang2023,
author = {Tang, Lu and Yin, Yue and Cao, Yuqi and Fu, Cong and Liu, Hening and Feng, Jingwen and Wang, Wei and Liang, Xing-Jie},
title = {Extracellular Vesicles‐Derived Hybrid Nanoplatforms for Amplified CD47 Blockade‐Based Cancer Immunotherapy},
journal = {Advanced Materials},
year = {2023},
doi = {10.1002/adma.202303835}
}
EUVIMED